Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Kellie Turner

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|January 27, 2026
Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast CancerEmmanuel Chigutsa, Sonya C Chapman, P Kellie Turner
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
Topoisomerase I interactive agentsP Kellie Turner, Lisa C Iacono, Clinton F Stewart
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Topoisomerase I interactive agentsMark N Kirstein, P Kellie Turner, Clinton F Stewart
European Journal of Drug Metabolism and Pharmacokinetics|November 10, 2017
Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and TasisulamEverett J Perkins, Maria Posada, P Kellie Turner, et al.
Clinical and Translational Science|June 20, 2023
Abemaciclib does not increase the corrected QT interval in healthy participantsJill C Chappell, Alan Y Chiang, Jane Royalty, et al.
Journal of Clinical Pharmacology|February 22, 2020
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic ModelingMaria M Posada, Bridget L Morse, P Kellie Turner, et al.
Clinical Pharmacokinetics|May 26, 2017
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer PatientsSonya C Tate, Amanda K Sykes, Palaniappan Kulanthaivel, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 26, 2020
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with CancerP Kellie Turner, Stephen D Hall, Sonya C Chapman, et al.
Cancer Chemotherapy and Pharmacology|July 28, 2005
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in childrenP Kellie Turner, Lisa C Iacono, John C Panetta, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 20, 2020
Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib PharmacokineticsEmmanuel Chigutsa, Siva Rama Prasad Kambhampati, Amanda Karen Sykes, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|January 27, 2026
Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast CancerEmmanuel Chigutsa, Sonya C Chapman, P Kellie Turner
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
Topoisomerase I interactive agentsP Kellie Turner, Lisa C Iacono, Clinton F Stewart
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Topoisomerase I interactive agentsMark N Kirstein, P Kellie Turner, Clinton F Stewart
European Journal of Drug Metabolism and Pharmacokinetics|November 10, 2017
Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and TasisulamEverett J Perkins, Maria Posada, P Kellie Turner, et al.
Clinical and Translational Science|June 20, 2023
Abemaciclib does not increase the corrected QT interval in healthy participantsJill C Chappell, Alan Y Chiang, Jane Royalty, et al.
Journal of Clinical Pharmacology|February 22, 2020
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic ModelingMaria M Posada, Bridget L Morse, P Kellie Turner, et al.
Clinical Pharmacokinetics|May 26, 2017
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer PatientsSonya C Tate, Amanda K Sykes, Palaniappan Kulanthaivel, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 26, 2020
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with CancerP Kellie Turner, Stephen D Hall, Sonya C Chapman, et al.
Cancer Chemotherapy and Pharmacology|July 28, 2005
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in childrenP Kellie Turner, Lisa C Iacono, John C Panetta, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 20, 2020
Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib PharmacokineticsEmmanuel Chigutsa, Siva Rama Prasad Kambhampati, Amanda Karen Sykes, et al.
Pageof 3